s1pr2 Antibody

What is S1PR2 and why is it a significant research target?

S1PR2 (Sphingosine-1-Phosphate Receptor 2, also known as EDG5) is a G-protein-coupled receptor that acts as a receptor for the lysosphingolipid sphingosine 1-phosphate (S1P). It plays a key role in the permeability and inflammatory responses of the vascular endothelium during endotoxemia and mediates various cellular processes including proliferation, survival, and migration . S1PR2 is one of five S1P receptor subtypes (S1P1-5), each exhibiting different cell specificity and tissue expression patterns . Its critical involvement in vascular inflammation makes it an important target for researchers studying inflammatory disorders, endothelial function, and related pathologies .

What types of S1PR2 antibodies are available for research applications?

Researchers can choose from several types of S1PR2 antibodies depending on their experimental needs. Polyclonal antibodies such as ABIN317746 are available that detect endogenous levels of EDG-5 protein, particularly the region surrounding Leu300 . These polyclonal antibodies typically react with human, mouse, and rat samples . For higher specificity, monoclonal antibodies like the Anti-S1PR2 Antibody clone 1C18 ZooMAb (Rabbit Monoclonal) target the N-terminal extracellular domain of S1PR2 . Additionally, conjugated antibodies are available with HRP, FITC, or biotin labels for specific applications requiring direct detection .

What are the common applications for S1PR2 antibodies in research?

S1PR2 antibodies are validated for multiple research applications:

These applications allow researchers to investigate S1PR2 expression, localization, and function in various experimental systems ranging from cell cultures to tissue sections .

How should I design validation experiments when using S1PR2 antibodies for the first time?

When validating a new S1PR2 antibody, implement a multi-step approach to ensure specificity and reliability. Begin with Western blot analysis using positive controls (tissues/cells known to express S1PR2, such as vascular endothelial cells) and negative controls (S1PR2 knockout tissues if available) . Compare bands with the expected molecular weight of S1PR2 (approximately 39 kDa). For immunostaining applications, perform parallel experiments with blocking peptides that correspond to the immunogen sequence (amino acids 293-353 for certain antibodies) .

Additionally, consider RNA interference experiments to confirm specificity by correlating reduced S1PR2 protein levels with knockdown efficiency. Validation should include cross-reactivity testing if you plan to use the antibody across multiple species, as reactivity may differ between human, mouse, and rat samples despite manufacturer claims . Document batch-to-batch variability by retaining aliquots of well-performing antibody lots for reference in future experiments.

What are the optimal experimental conditions for detecting S1PR2 in inflammatory models?

For inflammatory models, timing is critical when detecting S1PR2. Research indicates that S1PR2 expression and its downstream effects change dynamically during inflammatory responses . In LPS-induced endotoxemia models, significant differences in inflammatory markers between wild-type and S1PR2-null mice were observed at 18 hours post-induction, while earlier timepoints (2-6 hours) showed less pronounced differences .

For immunohistochemical detection in tissues subjected to inflammatory stimuli, focus on vascular endothelium, infiltrating leukocytes, and parenchymal cells, as these were identified as key sites of S1PR2-mediated effects . When designing in vitro experiments with endothelial cells, pre-treatment with inflammatory cytokines (TNF-α, IL-1β) may enhance S1PR2 detection. For optimal results, use freshly prepared samples and include appropriate time-course analyses to capture the dynamic nature of S1PR2 involvement in inflammatory processes .

How can I quantitatively assess S1PR2 activation in cellular systems?

Quantitative assessment of S1PR2 activation requires multiple methodological approaches:

• Downstream signaling pathway analysis: S1PR2 primarily couples to G12/13 and Gq proteins, activating the Rho/ROCK pathway. Measure RhoA activation using pull-down assays with the Rho-binding domain of Rhotekin .

• Calcium flux measurements: Since S1PR2 activation leads to calcium mobilization, use fluorescent calcium indicators (Fluo-4, Fura-2) to quantify changes in intracellular calcium levels following stimulation with S1P.

• Phosphorylation assays: Detect the phosphorylation status of downstream targets using phospho-specific antibodies in Western blot or ELISA formats.

• Transcriptional reporter assays: Engineer cells with reporter constructs containing response elements for transcription factors activated by S1PR2 signaling.

• Functional readouts: Measure endothelial permeability using transwell permeability assays with fluorescent dextran, which directly correlates with S1PR2 activation in vascular endothelium .

When interpreting results, remember that S1PR2 functions can be context-dependent, varying with cell type and physiological/pathological state .

What are common technical challenges when using S1PR2 antibodies and how can they be resolved?

Researchers frequently encounter several technical challenges when working with S1PR2 antibodies:

Challenge: High background in immunostaining
Solution: Optimize blocking conditions using 5-10% normal serum from the species in which the secondary antibody was raised. For tissues with high endogenous peroxidase activity, incorporate additional quenching steps using 0.3% H₂O₂ in methanol for 15-30 minutes .

Challenge: Multiple bands in Western blot
Solution: This may indicate post-translational modifications, splice variants, or non-specific binding. Verify specificities using gradient gels (8-15%) to better resolve protein bands. When using polyclonal antibodies like ABIN317746, consider pre-absorption with the immunizing peptide to confirm specificity . For recombinant monoclonal antibodies, multiple bands might indicate protein modification states .

Challenge: Inconsistent results between applications
Solution: Different applications require different epitope accessibility. For Western blotting, ensure complete protein denaturation; for immunohistochemistry, optimize antigen retrieval methods (heat-induced epitope retrieval in citrate buffer pH 6.0 works well for many S1PR2 antibodies) .

Challenge: Weak signal in tissue immunostaining
Solution: The epitope may be masked. Try multiple antigen retrieval methods and extend primary antibody incubation to overnight at 4°C. Amplification systems such as tyramide signal amplification may enhance sensitivity while maintaining specificity .

How should researchers interpret contradictory findings when comparing different S1PR2 antibodies?

When faced with contradictory results from different S1PR2 antibodies, conduct a systematic analysis:

First, compare the target epitopes of each antibody. The S1PR2 protein has distinct domains, and antibodies targeting different regions (N-terminal extracellular domain versus the region surrounding Leu300) may yield different results due to epitope accessibility or post-translational modifications . Create an epitope map documenting each antibody's target region and correlate this with your experimental findings.

Second, consider antibody format differences. Polyclonal antibodies provide broader epitope recognition but potentially lower specificity compared to monoclonal antibodies like ZooMAb clone 1C18 . Recombinant antibodies typically offer superior lot-to-lot consistency compared to traditional antibodies.

Third, implement validation strategies using genetic approaches. Compare antibody performance in wild-type versus S1PR2 knockout models to establish definitive specificity profiles . If knockout models are unavailable, siRNA knockdown systems can serve as alternative validation tools.

Finally, consider collaborative cross-validation with other laboratories to eliminate technique-specific biases. Document and report all findings, including contradictory results, to contribute to the broader understanding of S1PR2 antibody performance in the research community.

What statistical approaches are most appropriate for analyzing S1PR2 expression data across different experimental conditions?

When analyzing S1PR2 expression data across experimental conditions, select statistical methods based on your experimental design and data characteristics:

For comparing S1PR2 expression between two experimental groups (e.g., control vs. treatment), use parametric tests like Student's t-test for normally distributed data or non-parametric alternatives like Mann-Whitney U test when normality cannot be assumed. For multiple group comparisons (e.g., time-course studies or dose-response experiments), employ ANOVA followed by appropriate post-hoc tests (Tukey's or Dunnett's) to control for multiple comparisons .

When analyzing correlation between S1PR2 expression and physiological outcomes (such as endothelial permeability or inflammatory marker expression), calculate Pearson's or Spearman's correlation coefficients based on data distribution characteristics . For complex experimental designs involving multiple variables, consider multivariate analysis techniques such as principal component analysis or multiple regression models.

Power analysis should be performed a priori to determine adequate sample sizes for detecting biologically meaningful differences. For immunohistochemical quantification, use randomized sampling approaches and blinded scoring systems to minimize observer bias. When reporting results, include both statistical significance (p-values) and effect sizes to provide a complete picture of S1PR2 expression changes across experimental conditions .

How does S1PR2 function differ from other S1P receptor subtypes in experimental models?

S1PR2 exhibits distinct functional characteristics compared to other S1P receptor subtypes (S1P1, S1P3-5) in experimental models. While S1PR1 primarily couples to Gi proteins and promotes cell migration and survival, S1PR2 predominantly signals through G12/13 and Gq proteins, inhibiting cell migration and promoting vascular permeability . This functional antagonism between S1PR1 and S1PR2 creates a balanced regulatory system for vascular integrity.

In vascular inflammation models, S1PR2 knockout mice display reduced endothelial permeability and decreased expression of adhesion molecules (E-selectin, VCAM-1, ICAM-1) and inflammatory mediators (MCP-1) following LPS challenge . This contrasts with the protective effects of S1PR1 signaling in similar models. S1PR2's unique role in promoting vascular leakage makes it particularly relevant for studying conditions characterized by increased vascular permeability, such as sepsis and acute inflammatory disorders .

Unlike S1PR1 and S1PR3, which are widely expressed, S1PR2 shows more restricted tissue distribution with notable expression in vascular endothelium, liver, kidney, and certain immune cell populations . This pattern facilitates tissue-specific targeting in experimental interventions.

What are the most effective experimental models for studying S1PR2 functions in inflammation and vascular biology?

Several experimental models have proven effective for investigating S1PR2 functions in inflammation and vascular biology:

In vivo models:

• LPS-induced endotoxemia: This model reveals S1PR2's role in systemic inflammation. S1PR2-null mice show accelerated cytokine clearance and reduced inflammatory marker expression in liver, lung, and kidney following LPS challenge .

• Tissue-specific conditional knockout models: These allow investigation of cell-type-specific S1PR2 functions while avoiding developmental compensation mechanisms seen in global knockouts.

• Intravital microscopy models: These enable real-time visualization of leukocyte-endothelial interactions mediated by S1PR2 in inflamed microvessels.

In vitro models:

• Primary human or murine endothelial cell cultures: These allow investigation of S1PR2-mediated signaling in a controlled environment.

• Endothelial-leukocyte co-culture systems: These models help study S1PR2's role in cellular interactions during inflammation.

• Transwell permeability assays: These directly measure S1PR2's effects on endothelial barrier function using fluorescent tracers .

When selecting an appropriate model, consider that S1PR2 functions may vary depending on tissue context, inflammatory stimulus, and temporal dynamics of the response .

How can researchers effectively combine genetic and pharmacological approaches to study S1PR2 function?

A comprehensive understanding of S1PR2 function requires integrating both genetic and pharmacological approaches:

Genetic approaches:

• Global S1PR2 knockout models: These provide information about systemic effects of S1PR2 deficiency but may be confounded by developmental compensation .

• Conditional tissue-specific knockout systems: Using Cre-loxP technology, these models allow temporal and spatial control of S1PR2 deletion, enabling investigation of cell-type-specific functions.

• CRISPR/Cas9-mediated mutagenesis: This approach facilitates introduction of specific mutations to study structure-function relationships of S1PR2.

Pharmacological approaches:

• Selective S1PR2 antagonists: Compounds like JTE-013 can be used to acutely inhibit S1PR2 signaling, avoiding developmental compensation.

• Pathway-specific inhibitors: These target downstream effectors of S1PR2 (e.g., ROCK inhibitors) to dissect specific signaling pathways.

• S1P modulation: Manipulation of S1P levels using sphingosine kinase inhibitors or S1P lyase inhibitors allows investigation of receptor activation patterns.

Combining these approaches provides complementary insights: genetic models offer specificity but may trigger compensation, while pharmacological tools provide temporal control but may have off-target effects. A particularly powerful experimental design involves comparing pharmacological interventions in wild-type versus S1PR2 knockout backgrounds to confirm target specificity . When investigating complex phenotypes, consider using inducible systems that enable separation of acute versus chronic S1PR2 inhibition effects.

What emerging technologies are transforming S1PR2 antibody-based research?

Several cutting-edge technologies are reshaping S1PR2 antibody research:

Recombinant antibody technologies, exemplified by ZooMAb® antibodies, represent a significant advancement in S1PR2 research . Unlike traditional antibodies, these are manufactured using proprietary recombinant expression systems, ensuring exceptional lot-to-lot consistency and reproducibility. This standardization is particularly valuable for longitudinal studies investigating S1PR2 expression changes over time or across different experimental models.

Single-cell antibody-based technologies, including imaging mass cytometry and Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq), are enabling simultaneous analysis of S1PR2 protein expression and transcriptomic profiles at single-cell resolution. These approaches are revealing previously unrecognized heterogeneity in S1PR2 expression across cell populations during inflammatory responses.

Proximity labeling methods combined with S1PR2 antibodies are facilitating the identification of S1PR2 interaction partners in their native cellular context. Techniques like BioID or APEX2, where S1PR2 antibodies are used to validate fusion protein expression, are uncovering new components of S1PR2 signaling complexes that may serve as alternative therapeutic targets.

Automated high-content imaging platforms utilizing validated S1PR2 antibodies enable quantitative analysis of receptor trafficking, localization, and activation in response to various stimuli across thousands of individual cells. This approach provides statistically robust datasets for pharmacological screening of compounds targeting S1PR2 signaling.

How can multi-omics approaches enhance our understanding of S1PR2 function beyond antibody-based techniques?

Multi-omics approaches complement antibody-based S1PR2 research by providing comprehensive molecular insights:

Integrative proteomics and phosphoproteomics: These techniques map the dynamic changes in S1PR2-associated signaling networks following receptor activation or inhibition. By comparing wild-type and S1PR2-deficient systems , researchers can identify both direct and indirect targets of S1PR2 signaling, potentially revealing novel therapeutic intervention points for inflammatory disorders.

Spatial transcriptomics combined with S1PR2 immunohistochemistry: This approach correlates S1PR2 protein expression with transcriptional landscapes in specific tissue microenvironments. This is particularly valuable for understanding the cell type-specific effects of S1PR2 in complex tissues during inflammatory responses, as observed in liver, lung, and kidney during endotoxemia .

Metabolomics focused on sphingolipid metabolism: Since S1PR2 is activated by sphingosine-1-phosphate, comprehensive analysis of sphingolipid metabolites provides insights into receptor activation dynamics in various physiological and pathological contexts. Correlating metabolite profiles with S1PR2 expression and activation states reveals the interplay between ligand availability and receptor function.

Single-cell multi-omics: Combining single-cell transcriptomics, proteomics, and S1PR2 antibody-based detection enables detailed characterization of cellular heterogeneity in S1PR2 expression and downstream responses. This resolves conflicting observations that may arise from bulk analysis of heterogeneous cell populations.

When implementing multi-omics approaches, computational integration of diverse datasets represents a critical challenge. Developing bioinformatic pipelines that can correlate antibody-based S1PR2 quantification with other molecular datasets will be essential for extracting meaningful biological insights from these complex experimental designs.

What are the most promising translational applications for S1PR2 research in clinical medicine?

S1PR2 research holds significant translational potential across multiple clinical domains:

In vascular inflammatory disorders, S1PR2 inhibition represents a promising therapeutic strategy. Studies with S1PR2-null mice demonstrate reduced vascular permeability, decreased inflammatory marker expression, and accelerated resolution of inflammation following endotoxin challenge . These findings suggest that selective S1PR2 antagonists could mitigate vascular leakage and tissue damage in conditions like sepsis, acute respiratory distress syndrome, and ischemia-reperfusion injury.

The development of S1PR2-targeted molecular imaging probes using validated antibodies offers new opportunities for diagnosis and monitoring of vascular inflammation. Such probes could enable non-invasive visualization of S1PR2 expression in inflamed tissues, potentially serving as biomarkers for disease activity and treatment response.

Precision medicine approaches targeting S1PR2 signaling pathways may be tailored based on patient-specific S1PR2 expression patterns or genetic variants. Antibody-based companion diagnostics could identify patient subgroups most likely to benefit from S1PR2-targeted therapies.

Beyond vascular inflammation, emerging evidence suggests potential applications for S1PR2-targeted interventions in cancer, where S1PR2 mediates cell proliferation and survival , and in neuroinflammatory conditions, where S1PR2 influences blood-brain barrier integrity. The diverse biological functions of S1PR2 create opportunities for therapeutic repurposing across multiple disease contexts.

As translational research advances, validated S1PR2 antibodies will remain essential tools for preclinical target validation, pharmacodynamic monitoring in clinical trials, and development of diagnostic assays to support patient stratification strategies.